Thiotepa

Information about Thiotepa

Thiotepa is an intravenously or locally applied or injected alkylating agent which is currently used in the therapy of breast, ovarian and bladder cancer and for Hodgkin disease. 

Liver safety of Thiotepa

Thiotepa therapy has been associated with low rates of serum enzyme elevations during therapy and very rare instances of acute, clinically apparent injury.

Mechanism of action of Thiotepa

Thiotepa (thye' oh tep' a) is an ethylenimine similar in structure and activity to altretamine and is believed to act as an alkylating agent.  The alkylating agents act by causing modification and cross linking of DNA, thus inhibiting DNA, RNA and protein synthesis and causing programmed cell death (apoptosis) in rapidly dividing cells. 

FDA approval information for Thiotepa

Thiotepa was approved for use in the United States in 1959.  Current indications include ovarian and breast cancer and Hodgkin disease.  Thiotepa is also administered locally for bladder cancer, neoplastic effusions and malignant meningeal neoplasms. 

Dosage and administration for Thiotepa

Thiotepa is available generically in vials of 15 mg.  The dose recommended doses varies by indications, route of administration, and body weight. 

Side effects of Thiotepa

Thiotepa shares common side effects with other alkylating agents such as nausea, vomiting, diarrhea, alopecia, bone marrow suppression, rash and hypersensitivity reactions.

Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ

• Dailymed label info on Thiotepa
• FDA Thiotepa